Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2022-05-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
独立董事对公司第九届董事会第六次会议相关事项发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on the company's 2022 restricted stock incentive plan and related matters. It references compliance with stock exchange listing rules, company articles, and laws related to stock incentives. The content focuses on governance, approval, and assessment of a stock incentive plan rather than financial results or audit findings. The document length is short (1680 characters) and it is a formal opinion related to board matters, specifically about a stock incentive plan and its governance implications. This fits best under Board/Management Information (MANG), as it involves board-level decisions and independent directors' opinions on company governance and management incentives, rather than a full report or announcement of voting results or regulatory filings.
2022-05-10 Chinese
2022年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as an implementation and assessment management method for a restricted stock incentive plan of a company. It details the purpose, principles, scope, organizational responsibilities, performance evaluation indicators, procedures, and other rules related to the stock incentive plan. It is a governance-related document focusing on internal management and incentive mechanisms for directors, senior management, and key personnel. There is no indication that this is a financial report, earnings release, or regulatory filing. It is not an announcement of voting results or a proxy statement. The document is about governance practices and internal rules related to stock incentives and performance assessment. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2178 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2022-05-10 Chinese
第九届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the sixth meeting of the ninth board of directors of Northeast Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on various proposals related to a 2022 restricted stock incentive plan, and the authorization of the board to handle related matters. The document includes statements about compliance with laws and regulations and mentions that some proposals require shareholder approval at a general meeting. The content focuses on board decisions and governance matters rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, earnings release, or proxy solicitation. The document is an official announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG). The document length is 3418 characters, which is consistent with a detailed board meeting resolution announcement rather than a full report or presentation.
2022-05-10 Chinese
北京德恒律师事务所关于东北制药集团股份有限公司实际控制人增持股票的法律意见
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the actual controller's increase in shareholding in a listed company. It discusses compliance with securities laws, qualifications of the shareholder, details of the share increase, and information disclosure obligations. It is not a financial report, earnings release, or management discussion. It is a legal proceeding related document providing a formal legal opinion on a shareholding transaction. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 2991 characters, which is substantive and contains detailed legal analysis, not just an announcement or certification.
2022-04-28 Chinese
关于实际控制人增持计划实施完毕的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a share increase plan by the actual controller of the company, Mr. Fang Wei. It details the shareholding changes, the purpose of the increase, the implementation period, and compliance with relevant laws and regulations. There are no financial statements or detailed financial performance data included. The document is focused on shareholding changes by a major shareholder rather than a full financial report or earnings release. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short (1815 characters), and it is not merely an announcement of a report but a substantive notification of shareholding changes.
2022-04-28 Chinese
2022年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "东北制药集团股份有限公司 2022 年第一季度报告" which translates to "Northeast Pharmaceutical Group Co., Ltd. 2022 First Quarter Report." It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial metrics for the first quarter of 2022. The document explicitly states it is a quarterly report and mentions it is unaudited. The length of the document (13,096 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.